- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04842721
Effect of Hypertonic Saturated Saline Mouth Rinse on Covid-19 Virus in Vivo.
Effect of Prolonged Mouth Rinse With Hypertonic Saturated Saline Solution on the Naso-Pharyngeal Viral Load of Covid-19 Virus in Vivo.
Sars-Cov2 virus is transmitted through the respiratory route and by direct contact with contaminated surfaces and subsequent contact with nasal, oral or ocular mucosa. Many studies have found that the oral cavity and specifically the saliva may be a high-risk route for SARS-CoV-2 infection. Thus, strategies reducing salivary viral load could contribute to reduce the risk of transmission. Furthermore, studies have shown that SARS-CoV persists for two days in oral mucous membranes before its diffusion to the lower respiratory tract. This offers an interesting preventive and therapeutic window of opportunity for the control of this disease. In addition, Naso-pharyngeal viral load was linked with lung disease severity in a study of 12 patients with pneumonia.**. Some current studies around the world, as listed on ClinicalTrials.gov, are testing the effect of some common mouth rinses/gargles on the Covid-19 viral load, including Chlorhexidine gluconate, Hydrogen peroxide Povidone Iodine, Saline (1.102% w/v, slightly hypertonic) and Alcohol.
This study aims to test whether Prolonged Hypertonic Saline Mouth Rinse would reduce/eliminate*** the viral load in the Oro- Naso-Pharyngeal cavity, and could therefore be used as a strategy to reduce transmission risk in clinical and social settings.
The investigator hypothesizes that COVID-19-positive participants who use Hypertonic Saline Prolonged Rinse treatment will have an reduction/elimination of their Covid viral load, will develop a negative Covid test 7 days after intervention completion and will improve their clinical symptoms, potentially reducing lung disease severity.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The aim of this study is to determine if prolonged rinsing (30 minutes) of mouth without gargling using a Hypertonic Saturated Sodium Chloride solution would reduce/eliminate the Upper Respiratory viral load in Covid-19 infected patients compared to a placebo (Plain Water Rinse). Patients who have been tested positive for COVID-19 using Nucleic Acid Test via Nose or Throat Swabs within 7 days prior to the start of the trial will be instructed to use either of the two treatment arms (Active or Placebo) for 30 minutes twice daily for two days and retested for Covid 7 days after the last treatment
A randomized blinded controlled study, whereas a number of patients (at least 20) with clinically-confirmed Covid-19 infection within 7 days prior to the start of the study, are equally divided into 2 groups, Active and Control groups, using Active and Control Mouth rinses respectively. The Active Rinse is a 25 ml of Hypertonic Saturated Saline solution made by mixing 10 grams of Sodium Chloride (Table Salt) in 25 ml of Tap water with some salt crystals deposited. The Control Rinse is a 25 ml of Plain Tap Water. Each Patient of both groups will be asked to keep the solution still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing. After 30 minutes the solution will be spit out and mouth will be rinsed with plain water several times. The process will be done twice a day for 2 days. Patients of both groups will be tested once for Covid-19 7 days after the last treatment.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada
- Rafik Batroussy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Tested positive for Covid in the past 7 days
- Have the ability to perform mouth rinse twice daily for 2 days and to undergo Covid testing by Oro or Naso-Pharyngeal swabs.
- No need for a ventilator for oxygenation support
- Can understand and read English
- Lives in Alberta Canada
Exclusion Criteria:
- Requiring mechanical ventilation
- Unable to perform mouth rinses twice times daily for 2 days
- Patients that are tested negative for COVID-19
- Patients who have been eating or drinking within an hour before or after each session
- Use of an antiseptic mouthwash within 7 days prior or after the study
- Patient who are intubated or too sick to give consent for the study.
- Not able to speak in English or lacking the decision-making capacity to consent for study.
- Inability to comply with protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Hypertonic Saturated Saline Mouth Rinse Active Arm
The Active Rinse is a 25 ml of Hypertonic Saturated Saline solution made by mixing 10 grams of Sodium Chloride (Table Salt) in 25 ml of Tap water with some salt crystals deposited.
|
Each Patient of this groups will be asked to keep the solution still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing.
After 30 minutes the solution will be spit out and mouth will be rinsed with plain water several times.
The process will be done twice a day for 2 days.
|
PLACEBO_COMPARATOR: Plain Water Control Arm
The Control Rinse is a 25 ml of Plain Tap Water.
|
Each Patient of this groups will be asked to keep the water still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing.
After 30 minutes the water will be spit out.
The process will be done twice a day for 2 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Negative Covid PCR test results
Time Frame: 7 days
|
The number of Negative PCR tests post intervention will be compared between both the Active group and the Control group.
The Hypertonic Saturated Mouth Rinse intervention will be considered effective in reducing/eliminating Covid presence in the Oro-Nasopharyngeal area if the PCR Covid tests performed 7 days post termination of the study have more statistically-significant negative results in the Active group than in the Control group..
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Change in Clinical Symptoms
Time Frame: 7 days
|
A change in Covid Clinical symptoms (like fever, shortness of breath, dry cough, reduced lung functions, ..) in both the Active and Control groups will be monitored and statistically analyzed.
|
7 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Rafik Batroussy, BSc.Pharm., Independent
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on Hypertonic Saturated Saline Mouth Rinse Active Arm
-
Ain Shams UniversityNot yet recruiting
-
Ain Shams UniversityCompletedHead and Neck Cancer PatientsEgypt
-
University of Washington, the Collaborative Health...Cystic Fibrosis FoundationCompletedCystic FibrosisSpain, United States, Australia, Italy, France, Canada, Belgium, Denmark, Netherlands
-
Nada SherifAin Shams UniversityNot yet recruiting
-
James J LeeSanofiWithdrawn
-
Mundipharma Manufacturing Pte Ltd.Singapore Polytechnic (SP)Completed
-
The University of Texas Health Science Center at...South Texas Veterans Health Care SystemCompleted
-
Ohio State UniversityUnknown
-
Aswan University HospitalCompletedCesarean Section ComplicationsEgypt
-
Washington University School of MedicineSuspendedDiabetes Mellitus | Peripheral Arterial Disease | Critical Limb Ischemia | Lower Limb Amputation KneeUnited States